CpG-rich regions of DNA that are often associated with the transcription start sites of genes and that are also found in gene bodies and intergenic regions.
Over the past 25 years, an increasing amount of evidence has supported a role for epigenetic processes in cell biology and tissue physiology. The potential role of these epigenetic processes in human disease is exemplified by aberrant DNA methylation in cancer, both at individual genes and on a genome-wide scale. Initially, studies focused on candidate gene approaches to identify alterations occurring in distinct diseases; however, new powerful technologies, such as comprehensive DNA methylation microarrays 1, 2 and genome-wide bisulphite sequencing 3 , have recently emerged
. These have reinforced the notion of epigenetic disruption at least as a signature of human diseases 4 . An indication that alterations in epigenetic marks could be used as biomarkers -specifically DNA methylation -provided by the use of the hypermethylation events at the genes O 6 -methylguanine-DNA methyltransferase (MGMT) 5 in glioma and glutathione S-transferase pi 1 (GSTP1) 6 in prostate cancer; these hypermethylation events have been shown to be effective for determining an appropriate treatment choice in glioma and in the diagnosis of prostate cancer, respectively. The detection of epigenetic alterations is therefore a promising tool for the diagnosis and prognosis of disease and for the prediction of drug response.
This Review focuses on epigenetic profiling at the level of DNA methylation 7, 8 . There is an emphasis on neoplasia, as this is the area in which using these epigenetic markers is best characterized, but many of these concepts are applicable to other disorders, such as neurological, metabolic and cardiovascular disorders and autoimmune diseases. DNA methylation marking repressed genes is a frequent event in development, differentiation and tissue homeostasis. Cancer cells present a global loss of DNA methylation centred in hypomethylated blocks and regional hypermethylation, especially in CpG-rich contexts 8, 9 . For cancer, recent evidence has given an indication of the altered DNA methylation events beyond classical promoter hypermethylation of CpG islands of tumour suppressor genes 10 . The early signs are that this knowledge will be useful in practical clinical situations, such as in the diagnosis of cancers of unknown primary origin, the screening for malignancies in high-risk populations or biomarker-based selection of the patients that should receive treatment with epigenetic drugs. Furthermore, there is a growing list of mutated chromatin remodeller genes that contribute to the tumorigenesis process and that may be targeted with drugs in the future for cancer treatment 11 
. In the future, studying chromatin structure may provide useful insights for diagnosis and prognosis (but this requires further research and is not discussed here).
This Review provides an insight into epigenetic alterations implicated in diagnostics, prognostics and prediction to drug response and their current use in clinical settings. First, an overview of what makes a suitable DNA-methylation-based biomarker is presented, including a consideration of the non-invasive tissues that may be used to profile these. Then the applications of DNA profiling in disease diagnosis followed by disease prognosis and prediction to drug response are presented, including a consideration of relevant examples at every stage. Finally, future directions for the development of relevant biomarkers and their applications are discussed.
DNA methylation profiling for disease diagnosis
The dynamic nature of DNA methylation. DNA methylation is a dynamic modification that is put in place and removed by a range of enzymes that may be targeted for disease treatment (BOX 2) ; this is reviewed elsewhere 4, 11, 12 . Given their dynamic nature, epigenetic disease biomarker genes have to be determined by considering inter-individual and intra-individual variations. In this respect, the definition of reference DNA methylation data sets will be of a high value, facilitating biomarker selection by initially defining suitable sites -that is, sites that show consistent levels of DNA methylation in healthy individuals. Comprehensively studying the profiles of different healthy individuals and tissue types enables us to estimate the variance of a particular CpG site or of regions such as promoters. Reference data sets are now being created in consortia such as Blueprint, the International Human Epigenome Consortium (IHEC) and Roadmap using high-resolution technologies that are summarized in BOX 1 (REFS 13, 14) . Focusing on normal tissue types, these joint efforts aim freely to release reference data sets of integrated epigenomic profiles of stem cells, as well as developmental and somatic tissue types to the research community. As a paradigm, the estimation of genetic variance in the human population and the identification of SNPs greatly improved mutational analysis for disease identification by excluding false-positive hits for disease-linked mutations before screening. Concordantly, filtering for loci that are unstable in DNA methylation between individuals excludes unsuitable CpG sites before biomarker candidate selection approaches. Systematic screening of reference data sets obtained from different individuals will enable us to identify and to exclude variable CpG sites and regions, highly facilitating future biomarker selections. Furthermore, owing to tissue-specific DNA methylation, particular regions are unsuitable markers in biological fluids, as the cancer-specific hypermethylation event might be occluded by hypermethylation of the cells that are present in the fluid.
The suitability of epigenetic markers versus genetic markers as biomarkers. Although aberrant epigenetic modifications affect a broad range of disease types, cancer presents the best characterized examples: in addition to genetic mutations, epigenetic alterations have been noted during tumour formation and progression 15 . In particular, changes in DNA methylation have been correlated with the alteration of gene expression of some tumour-suppressor genes, suggesting that alterations of DNA methylation can be exploited in cancer diagnosis 16 (TABLE 1). In comparison with genetic approaches, such as mutational analysis, DNA-methylation-based diagnostic techniques present advantages with regard to their clinical application. For a given marker gene, DNA hypermethylation analysis focuses on a rather small promoter region as hypermethylation only occurs at CpG islands, facilitating detection, whereas genetic studies often have to cope with large regions of interest, as numerous different point mutations occur throughout the length of the gene. In general, DNA methylation alterations occur at higher percentages of tumours than genetic variations, resulting in a higher sensitivity even in single-gene DNA methylation studies 17 . Also, diseases other than cancer, such as neurodevelopmental and metabolic disorders and autoimmune diseases, reveal profound alterations in DNA methylation profiles, whereas gene mutations are rarely
Box 1 | The technology revolution in epigenetic profiling
Whole-genome bisulphite sequencing Whole-genome bisulphite sequencing (WGBS) allows for an unbiased assessment of the profile of DNA methylomes. Using bisulphite-treated DNA converting unmethylated cytosines into thymidines 82 , next-generation sequencing (NGS) technology is used to obtain a complete overview of CpG methylation level at base-pair resolution. Originally applied in Arabidopsis thaliana 83 , WGBS has been used to analyse DNA methylation variation between embryonic stem cells (ESCs) 84, 85 , induced pluripotent stem cells (iPSCs) 86 and differentiated cells 87 . Subsequent studies have revealed detailed information about healthy somatic tissues and associated cancer methylomes for breast 7 and colorectal cancers 8, 9 .
Restriction enzyme-enriched sequencing techniques
Although less comprehensive than whole-genome bisulphite sequencing, reduced representation bisulphite sequencing (RRBS) is an efficient technique that is suitable for obtaining information from most CpG islands and information about sequences outside CpG-rich regions 88 . This technique reduces the number of non-informative reads by DNA digestion using a methylation-insensitive restriction enzyme (MspI). As MspI contains a CpG site in its recognition sequence motif, each sequencing read contains at least one informative position. RRBS has been used to identify changes during cell differentiation and was also intensively applied in the Roadmap project 89 , providing detailed information about ESCs and iPSCs 90 . Restriction-enzyme-based comprehensive high-throughput arrays for relative DNA methylation (CHARM) uses the methylation-dependent specificity of the methylationsensitive restriction enzyme McrBC with subsequent analysis on tiling arrays. Using genome-weighted smoothing, CHARM allows quantitative analysis of genomic regions rather than single base pairs 91 . CHARM technology was carried out to establish the impact of CpG island shores on tumorigenesis of colorectal cancer 92 but also for intense studies of iPSCs [93] [94] [95] and the epithelial-mesenchymal transition 96 .
Affinity-enrichment-based sequencing techniques
Methylated DNA binding domain sequencing (MBD-seq) 97, 98 and methylation DNA immunoprecipitation sequencing (MeDIP-seq) 99 ,100 combine the advantages of NGS and enrichment of methylated regions by immunoprecipitation. Both techniques were successfully applied to identify aberrantly methylated disease-related CpG sites 101 . Precipitation-based techniques are suitable for covering large parts of the genome in a quantitative manner, especially in combination with methylation-sensitive restriction enzyme sequencing (MRE-seq) 102, 103 . A detailed comparison of sequencing-based technologies showed all methods to yield comparable methylation calls, although they differed substantially in terms of resolution and costs 3 .
DNA methylation arrays
CpG-specific array technology is an alternative option for determining a genome-wide DNA methylation profile. The latest HumanMethylation 450 beadchip assay (Illumina) allows for the high-resolution, genome-wide DNA methylation profiling of human samples to be carried out, covering 99% of all RefSeq genes and approximately 450,000 CpGs overall 1, 2, 104 . The array analyses CpG islands, shores (the 2 kb flanking the CpG islands) and shelves (the 2kb flanking the shores) as well as island-independent CpGs. Although focused on gene promoters and intragenic regions, there are also additional sites of potential interest, such as DNaseI-sensitive and enhancer regions. Compared with sequencing approaches, DNA methylation arrays are a low-cost alternative, which allows the profiling of a large number of samples, although at a reduced resolution.
Locus-specific DNA methylation analysis
In addition to genome-wide technologies, locus-specific identification of the DNA methylation level is a cost-effective strategy, especially if single genes are already established as biomarkers for diagnosis or prognosis. Sequencing-based technologies such as direct bisulphite and pyrosequencing but also alternatives such as methylation-specific-PCR-based and matrix-assisted laser desorption/ionization (MALDI)-mass-spectrometry-based analysis [105] [106] [107] [108] are suitable for reliably assessing DNA methylation levels.
Personalized medicine
Therapeutic decisions based on genetic and epigenetic information of individual patients detected, which makes epigenetic analysis applicable to a broader range of diseases [18] [19] [20] . Most importantly, a combination of DNA methylation and genetic analyses could exploit the advantages of both techniques, as has recently been shown for the diagnosis of colorectal cancers 21 . Although DNA hypomethylation is also a major epigenetic alteration in cancer cells, its diagnostic use is limited because a reduction of DNA methylation is technically more complicated to detect than a gain of a signal. Broadly used techniques, such as methylation-specific PCR (MSP), reliably identify a hypermethylation event; however, a quantitative detection, as is required for DNA hypomethylation analysis, is technically more challenging and more difficult to standardize. However, DNA hypomethylation of the repetitive element LINE-1 has frequently been observed and is associated with drug response to fluoropyrimidines in colorectal cancer patients 22 . In addition, loss of imprinting at the insulin-like growth factor 2 (IGF2) gene locus is a frequent event in cancer and has potential use for colon cancer diagnosis 23, 24 . Early tumour detection is one of the major factors in successful cancer treatment. Using non-invasive methods, such as the analysis of blood, stool, saliva or urine samples, has clear advantages over invasive techniques, such as biopsies. Tumour DNA can enter biological fluids in different ways: tumour cells can be directly released from the tissue of origin; necrotic tumour cells are engulfed by macrophages by phagocytosis and subsequently the tumour cell enters the blood or urethra; or free tumour DNA directly reaches the fluids by cell lysis. Analysis of epigenetic alterations can then be carried out by these non-invasive methods 25 .
Box 2 | Epigenetic modifiers: potential drug targets

Epigenetic drugs in clinical use and trials
Tumours that display global epigenomic alterations might also benefit from therapies that restore these global patterns. Some of the modifying enzymes that put in place the mark are mutated in disease and can be targeted by specific molecules, representing the first examples of the development of personalized medicine therapies that combine genomic and epigenomic knowledge. Considering the dynamic and reversible nature of epigenetic marks, they represent an attractive target for personalized therapy. However, treatment with currently approved epigenetic drugs (DNA methyl transferase (DNMT) and histone deacetylase (HDAC) inhibitors) is rather broad, and yet to be defined epigenetic cancer subtypes might respond differently. Here, high-resolution profiling might improve the treatment efficiency by guiding the therapy decision. Currently approved epigenetic treatments are described below, although readers are referred elsewhere for further detailed discussion of these 11, 12, 109 . To date, four epigenetic drugs have been approved by the US Food and Drug Administration (FDA): two DNMT inhibitors and two HDAC inhibitors. 5-azacytidine (5-aza-CR; manufactured by Celgene as Vidaza) was approved in 2004 specifically to inhibit DNA methylation, and two years later its variant 5-aza-2ʹ-deoxycytidine was approved (5-aza-CdR; manufactured by Eisai as Dacogen). Both were approved for the treatment of higher-risk myelodysplastic syndrome. In addition, S110 (REF. 110 ), which is a dinucleotide containing 5-aza-CdR and is suggested to have enhanced stability and efficiency, complements the list of DNMT inhibitors that are in use or that are being tested in clinical trials. Vorinostat (Merck) -an FDA-approved HDAC inhibitor for the treatment of cutaneous T cell lymphoma (CTCL) 111,112 -was also confirmed to induce complete response or haematological improvement in AML patients 113 . Besides Vorinostat, Romidepsin (Celgene), another HDAC inhibitor, revealed remarkable efficacies in the treatment of cutaneous T cell lymphoma (CTCL) patients 114 . Two additional HDAC inhibitors -Panobinostat (Novartis) and CI-994 (Pfizer) -are currently being tested in clinical phase III trials for the treatment of lymphomas and non-small-cell lung cancer (NSCLC), respectively.
A new generation of targeted epigenetic drugs
Owing to an increased resolution of genomic and epigenetic profiling methods, targeted epigenetic treatments, such as the specific inhibition of enzymes by small molecules, are being developed, adding to the drug arsenal to improve drug performance further while reducing toxicity to healthy tissue. Specific treatments that target epigenetic modifiers are the subject of current investigation, and the most recent examples are briefly considered in the following section.
Bromodomain and extra-terminal domains (BETs) are adaptor molecules that are involved in chromatin-dependent signal transduction, resulting in transcriptional initiation and elongation. The bromodomain family member BRD4 has been shown to be involved in gene fusions in squamous carcinomas and leukaemia. The small molecule JQ1 has been established as a potent inhibitor of BRD4, and JQ1 treatment showed strong antiproliferative effects in cell line and xenograft models that harboured BRD4 fusion 115 . Chromosomal translocation involving mixed lineage leukaemia (MLL), which is a histone lysine methyl transferase, is an initiator of aggressive forms of leukaemia with extremely poor prognosis. MLL fusion partners, especially members of the super elongation complex (SEC), such as AF4, AF6, AF9, AF10 and ENL, have been identified as interaction partners with BET proteins. Using the small-molecule inhibitor of the BET family I-BET151 causes displacement of BRD3-BRD4 and SEC from chromatin, followed by inhibition of co-activator function and subsequent repression of key oncogenes, such as MYC, B cell CLL/lymphoma 2 (BCL2) and cyclin-dependent kinase 6 (CDK6) 116 . Fusion products of translocated MLL genes also initiate aberrant recruitment of DOT1L, which is a histone methyltransferase that is involved in histone H3 lysine 79 (H3K79) methylation, to MLL target promoters, resulting in mislocalized enzymatic activity 117, 118 . In patients harbouring the translocated MLL genes, altered DOT1L activity functions as a downstream event associated with the activation of leukaemogenic genes such as homeobox A9 (HOXA9) and Meis homeobox 1 (MEIS1). Recently, Daigle and co-workers 119 developed the small molecule, EPZ004777, which specifically inhibits the H3K79 methylation activity of DOT1L. EPZ004777 treatment results in selective killing of leukaemia cells that harbour the MLL translocation in mouse xenograft models.
Prostate-specific antigen (PSA). A serine protease of the kallikrein gene family that is secreted into seminal fluid by prostatic epithelial cells and is found in the serum. As it is almost exclusively a product of prostate cells, measurement in blood has proved to be useful as a tumour marker for diagnosis of prostate cancer and monitoring the effectiveness of treatment. established GSTP1 as a promising biomarker of prostate cancer with a sensitivity of 82% and a specificity of 95% 33 . As GSTP1 hypermethylation was detected in 69% of proliferative inflammatory atrophy lesions (precursor lesions for the development of prostate cancer and/ or high-grade prostatic intraepithelial neoplasia) in an analysis of 27 patient samples, it is thought to be an early event in tumorigenesis, underlining its importance for diagnosis 34 . Initially, Goessl and colleagues 35 confirmed the presence of GSTP1 hypermethylation in urine (36%; 4 out of 11 subjects), serum (72%; 23 out of 32 subjects) and ejaculate (50%; 4 out of 8 subjects) from patients with prostate cancer. Later, the GSTP1 hypermethylation was confirmed in independent studies that detected 32%, 42% and 13% of subjects displaying hypermethylation by analysing 62, 168 and 83 serum samples from patients with prostate cancer, respectively [36] [37] [38] . Here, a combination with testing of the serum-based biomarker prostatespecific antigen (PSA) could increase the sensitivity of both methods in the diagnosis of prostate cancer 38 . GSTP1 hypermethylation in urine was further confirmed with sensitivities of 27% and 50% in studies The diagnostic potential of histone marks faces more technical challenges compared with the diagnostic potential of DNA methylation, as histone modifications are less-stable modifications and have been shown to be more dynamic 26, 27 . The assessment of histone marks is more difficult to apply and to standardize, because it relies on using antibodies, which vary in performance.
GSTP1 hypermethylation: a prostate cancer diagnosis marker. Prostate cancer is an example in which noninvasive diagnostics is showing promise. The most promising candidate for a biomarker for prostate cancer diagnosis and prognosis is the DNA hypermethylation at an enzyme that is involved in cellular detoxification of xenobiotics and carcinogens: the glutathione S-transferase pi 1 (GSTP1) (FIG. 1) . Having first been identified as being hypermethylated in cancer in 1994 (REF. 28 ), GSTP1 was confirmed to be mainly repressed in prostate cancer 6, [29] [30] [31] [32] and also in additional cancer types, albeit to a lesser extent 6 . The gain of DNA methylation was consistently validated in over 30 independent studies, and a meta-analysis pooling these ~3,500 subjects that analysed 22 and 36 prostate cancer patient samples, respectively 39, 40 , and diagnosis was technically improved by prostatic massage 41 and the combination of analysis of hypermethylation at different markers, such as cyclin-dependent kinase inhibitor 2A (CDKN2A, which encodes the protein p16), ARF and MGMT 42, 43 . Meta-analysis of 22 studies that analysed the value of GSTP1 as a biomarker for prostate cancer in biological fluids, including plasma, serum and urine, revealed a high specificity of 89% but showed modest sensitivity (52%) 44 . Analysing GSTP1 hypermethylation in biological fluid presents a promising alternative to conventional methods of detection of prostate cancer. In particular, the combination of GSTP1 with additional biomarker genes and PSA testing could highly improve the sensitivity of diagnosis.
In addition to GSTP1, other genes exhibit a high incidence of hypermethylation in prostate cancer and can be detected in biological fluids 37, 38, 42 . In particular, the following genes were confirmed to gain DNA methylation to similar extents as those detected for GSTP1 (promoter hypermethylation levels given in brackets): the tumour suppressor adenomatous polyposis coli (APC; 83-90%), RAS association (RalGDS/AF-6) domain family member 1 (RASSF1; 68-95%), prostaglandin-endoperoxide synthase 2 (PTGS2; 68-88%), mediator complex subunit 15 (MED15; also known as TIG1; 96%) and multidrugresistance protein 1 (MDR1; also known as ABCB1; 80-88%) 29, 31, 32, 45 . Especially in combination, these markers were able to distinguish reliably between primary cancer tissue and benign tissue 29, 31, 45 . Combining DNA hypermethylation of GSTP1, APC, RASSF1, PTGS2 and MDR1 resulted in both sensitivity and specificity of up to 100% of 73 tested prostate cancer specimens 29 . Using only a subset of hypermethylated markers (namely, GSTP1, APC and PTGS2) led to a sensitivity of 71-91% and to a specificity of 93-100% in the detection of prostate cancer in 53 specimens 31 . Even the combination of only methylation analysis of GSTP1 and TIG1 in 80 cancer samples resulted in 93% sensitivity and 85% specificity of diagnosis and prognosis of prostate cancer, respectively 45 . Specifically, the combination of hypermethylation of the above mentioned markers presents significant correlation with pathological grade and stage: for example, hypermethylation of GSTP1, APC and PTGS2 gene loci correlated with prognostic indicators such as pathologic stage 31 . Although these studies analysed hundreds of cancer samples and clearly suggest the great potential of these markers, large-scale studies and comprehensive meta-analysis, as carried out for GSTP1, are needed to establish the potential markers as being suitable for clinical use in primary tissues 29, 31, 45 and biological fluids 37, 38, 42 .
Non-invasive DNA methylation markers for diagnosis of other cancers. In addition to prostate cancer, other biomarkers from cancers of diverse origins have been identified in biological fluids. Colorectal cancer (CRC) frequently displays hypermethylation of APC, MGMT, RASSF2 and WNT inhibitory factor 1 (WIF1). Analysing the hypermethylation levels of these genes in 243 primary tissues and corresponding plasma samples of sporadic colorectal cancer patients estimated a detection sensitivity of 87% and a specificity of 92% for colorectal cancer diagnosis in patient plasma 46 . Another study that screened for DNA methylation candidate markers differentially methylated between primary CRC and nonpathologic tissue identified the hypermethylation of transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2), nerve growth factor receptor (NGFR) and septin 9 (SEPT9) in cancer samples 47 . Their potential as blood-based biomarkers was validated in 133 CRC samples and 179 healthy control individuals. The use of SEPT9 hypermethylation as a biomarker for -methylguanine-DNA methyltransferase (MGMT) protects normal cells against transition mutations by removing alkyl groups (red squares), which have been introduced by carcinogens such as nitrosamides, from guanine bases. Hypermethylation of MGMT is correlated with blocked gene expression, leading to the accumulation of alkylated guanines and subsequent DNA damage. However, hypermethylated MGMT in glioblastomas is a predictor of good response to DNA-alkylating drugs, such as carmustine and temozolomide, as an active MGMT is able to repair modified bases introduced by the therapy. Hypermethylation of MGMT is used as biomarker for drug response in glioblastoma biopsies but can also be detected in serum. Glutathione S-transferase pi 1 (GSTP1) has been established as biomarker for prostate cancer diagnosis and prognosis. It is involved in cellular detoxification of xenobiotics and carcinogens (red circles). In a normal context, GSTP1 actively removes damaging agents from the cell. Hypermethylation of GSTP1 in tumours is correlated with gene repression and subsequent cellular accumulation of xenobiotics and carcinogens, thereby favouring tumorigenesis. Hypermethylation of GSTP1 is used as a biomarker for malignant cells in prostate biopsies but can also be detected in urine and serum.
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Translation Translation Translation blood-based CRC diagnosis was later confirmed in an independent study that screened 50 CRC patients; cancer was detected with a sensitivity of 90% and a specificity of 88% using the methylation at this gene as a marker 48 . Using stool as a non-invasive screening material for 84 CRC patients revealed hypermethylation of TFPI2 as a CRC marker. The presence of hypermethylation at TFPI2 could detect CRCs in samples from patients with cancer with a sensitivity of 76-89% 49 . Gene promoter hypermethylation has also been established as a biomarker candidate for patients with glioblastoma 50 and patients with non-small-cell lung cancer (NSCLC) 51 . Glioblastomas could be detected with a sensitivity of 95% and a specificity of 60% by analysing MGMT promoter methylation in the serum of 37 patients 50 . Here the patient serum DNA hypermethylation levels of MGMT were highly correlated with the primary tissue levels and were able to predict a lack of cancer progression and overall survival of the patient. The detection of MGMT hypermethylation in combination with CDKN2A and GSTP1 hypermethylation allowed for the detection of NSCLC with 73% sensitivity but analysed a small cohort of 15 samples 51 . Using saliva as a source of biomarkers in 30 patients suffering from head and neck cancer identified the combination of MGMT, CDKN2A and deathassociated protein kinase 1 (DAPK1) hypermethylation as powerful biomarkers, detecting 65% of tumours 52 . In follow-up studies, the number of potential biomarkers was complemented by homeobox A9 (HOXA9) and nidogen 2 (NID2) hypermethylation, showing detection sensitivities of 75% and 87%, respectively, and specificities of 53% and 21%, respectively, giving a higher sensitivity when tested in combination 53 . The detection of DNA methylation alteration in biological fluids represents a promising tool for noninvasive cancer detection. However, many candidates present a low specificity, which results in a false-positive diagnosis. Reference data sets allow for the initial exclusion of genes that show high inter-individual variation or high levels of basic methylation, making it difficult to detect a gain in cancer patients. Improving candidate selection by using reference DNA methylomes could accelerate biomarker discovery and specificity by minimizing the number of unsuitable markers for prognostic DNA methylation approaches selected for further investigation.
Genome-wide epigenetic technologies might also facilitate the identification of cancers of unknown primary origin. Following the detection of metastatic diseases, it is crucial for the success of the treatment and, in turn, for the prognosis to identify the primary origin of the tumour. In a comprehensive study, analysing DNA methylation of 1,505 CpG sites in 1,628 human samples, Fernandez et al. 20 determined tissue-and cancerspecific fingerprints and were able to assign a tissue of origin for 69% of the cancers of unknown primary origin analysed (FIG. 2) .
DNA methylation in the diagnosis of non-cancer diseases.
It is of note that DNA methylation profiling is also able to identify differentially methylated genes in a non-cancer context 54 (TABLE 2) . Twin studies are a powerful approach as, despite their identical genetic background, twins have differences in DNA methylation 55 . Three studies of monozygotic twins who were discordant for disease development revealed surprising epigenetic differences. Monozygotic twins who were discordant for systemic lupus erythematosus (SLE), which is an autoimmune disorder, revealed differences in DNA methylation of blood cells in a number of genes that are involved in immune function 18 . A similar study setup using blood from monozygotic twins who were discordant for childhood-onset type 1 diabetes identified a disease-specific DNA methylation signature, which was subsequently validated in a cohort outside the twin context 56 . Differential DNA methylation markers may also help in the diagnosis of diseases in which only a few genetic mutations have been linked to the development of the disease, such as Alzheimer's disease 57 . Comparing DNA methylation levels in neurons of monozygotic twins who were discordant for the disease unravelled global loss of methylation levels in patients compared with their healthy relatives, suggesting a role for an altered epigenetic landscape in Alzheimer's disease 58 . In this regard, the incidence of neurodegenerative disorders increase with advanced age, and recent data obtained by whole-genome bisulphite sequencing show important DNA methylation changes in nonagenarians and centenarians 59 . In all of these studies, how these changes might contribute to future diagnosis has to be clarified in follow-up studies.
Moving towards clinical epigenetic tests. Although none of the assays for epigenetic diagnostics has yet achieved approval by authorities, there are commercial tests for laboratory usage and clinical trials available. In particular, these take advantage of the predictive potential of hypermethylation of GSTP1 and APC for prostate cancer diagnosis. In addition, assays that detect loss of imprinting of IGF2 as a risk factor for colon cancer and aberrant DNA methylation patterns, causing the neurodevelopmental disorders of genomic imprinting Prader-Willi syndrome and Angelman syndrome, are commercially available. Note, however, that the alterations in methylation here occur in the germline and are inherited rather than somatic mutations. Furthermore, in moving to genome-wide DNA methylation profiling with ever-decreasing costs per sample, DNA methylation screening will probably soon prove to have great advantages over current diagnostic methods, such as prostatespecific antigen testing for prostate cancer diagnosis.
DNA methylation profiling for disease prognosis
In addition to its diagnostic potential, DNA methylation is informative for patient prognosis in terms of tumour recurrence and overall survival. This is certainly true for single-gene loci; however, recent genome-wide profiling has also indicated a strong potential for genome-wide profiles to predict outcome (FIG. 2) .
Single-loci DNA methylation profiling for disease prognosis. Single-loci strategies amplify the knowledge obtained from tumour diagnosis by combining tumour markers with clinical follow-up data to try and identify correlations between epigenetic markers and prognosis. Using a single-loci approach and a cohort of 51 patients with recurrence within 40 months and 116 patients without tumour recurrence in that period, the hypermethylation of four genes -CDKN2A, cadherin 13 (CDH13), RASSF1 and APC -was able to predict tumour progression in stage 1 NSCLC independently of other clinical features, such as stage, age and smoking history; in a multivariate model, promoter DNA hypermethylation of these genes was associated with early tumour recurrence 60 . The results were confirmed in an independent patient cohort of 20 samples 60 .
Further examples of single-gene loci that indicate outcome include hypermethylation of the genes encoding NSD1, DAPK1, epithelial membrane protein 3 (EMP3) and CDKN2A; promoter hypermethylation of these genes has been linked to poor outcome in neuroblastomas for NSD1, lung cancer for DAPK1, brain tumours for EMP3 and CRC for CDKN2A 11 . DNA methylation profiling for metastasis identification. Crucial to prognosis is the detection and treatment of tumour cells that have disseminated from the point of origin. DNA methylation alterations in metastatic cancer cells were first reported at E-cadherin for breast cancer 61 and extended to an additional member of the cadherin family (cadherin 11) in head and neck cancer and melanoma samples 62 . Another study identified microRNA gene hypermethylation profiles that are characteristic of human metastasis 63 .
DNA methylomes in prognosis. Cancer cells display a global loss of DNA methylation; however, CpG-rich gene promoters are frequently targets of DNA hypermethylation associated with tumour-suppressor gene silencing and cancer formation and progression. Thus, comprehensive DNA methylation profiling presents a potent tool to profile regions with possible prognosis predictive potential (BOX 1; FIG. 2) . As high-resolution data serve not only as a source for cancer-subtype-specific profiles but also for the identification of powerful single epigenetic biomarker genes and gene combinations at various stages of disease, many types of clinical applications can benefit from this advanced screening strategy. The prognostic potential of DNA methylation profiling was initially reported for childhood acute lymphoblastic leukaemia samples 64 . Determining the DNA methylation level of 401 patients and 1,320 CpG sites (using GoldenGate from Illumina) allowed the classification of the patients into acute lymphoblastic leukaemia subtypes. Furthermore, DNA methylation profiling allowed the stratification of patients with high hyperdiploidy and translocation t(12;21) into two subgroups with different probabilities of relapse. In particular, DNA methylation profiling of 40 genes permitted the identification of pathologically distinct disease subtypes and the identification of 20 genes at which methylation predicted 
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For further details, see REF. 53 . AIM2, absent in melanoma 2; CD154, also known as CD40LG; CLTA4, clathrin, light chain A; CREBBP, CREB-binding protein; DNMTB, DNA (cytosine-5)-methyltransferase 3 beta; DR3, also known as TNFRSF25; EP300, E1A-binding protein p300; FMT1, fragile X mental retardation 1; FXN, frataxin; IL-6, interleukin 6; L1, also known as FAM49B; MECP2, methyl-CpG-binding protein 2 (Rett's syndrome); NEP, also known as MME; NFκB1, nuclear factor-κ B p105 subunit; PADI2, peptidyl arginine deiminase, type II; PRF1, perforin 1 (pore-forming protein).
disease relapse 64 . Here, DNA methylation profiling therefore resulted in subtype-specific and predictive signatures with potential use as future prognostic biomarkers for childhood acute lymphoblastic leukaemia.
A more comprehensive study that analysed ~14,000 genes (using Infinium 27K from Illumina) classified 154 normal and CRC samples according to their DNA methylation profile 65 . Strikingly, this study identified subgroups correlating with prognostic markers such as mutL homologue 1, colon cancer, nonpolyposis type 2 (MLH1) methylation and v-raf murine sarcoma viral oncogene B1 (BRAF), TP53 or v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) mutation, suggesting that DNA methylation analysis might contribute to CRC classification, and a combination of epigenetic and genetic analysis might further improve the accuracy of prognosis.
Another study, focusing on the analysis of developmental regulated Polycomb target genes (PCTGs) and loci heavily methylated in embryonic stem cells (MESCs) in 1,475 samples using the Infinium 27k technology, identified both regions to be differentially methylated in various cancer types 66 . Hypermethylation of PCTGs was observed as an early event in tumorigenesis even detectable before neoplastic changes occur, hence suggesting PCTGs as potential diagnostic markers. In contrast, hypomethylation of MESCs progressed concomitantly with tumour stage and correlated with poor prognosis in breast, ovarian, cervical and endometrial cancers.
The DNA methylation profiling of 248 breast cancer samples identified a previously unrecognized subtype associated with T lymphocyte infiltration. Importantly, profiling immune genes determined a prognostic value of the profile. In particular, the promoter hypermethylation of lymphocyte transmembrane adaptor 1 (LAX1) and CD3D significantly correlated with survival in certain breast cancer subtypes 67 . Aiming to identify a DNA methylation signature related to breast cancer metastasis, 39 primary breast tumour specimens were analysed using the Infinium 27K platform 68 . Strikingly, DNA methylation profiling determined two distinct groups with a substantially different association to metastasis-free survival. Assessing the DNA methylation of only three genes of the methylation signature -rho guanine nucleotide exchange factor (ARHGEF7), ALX homeobox 4 (ALX4) and RAS-protein-specific guanine nucleotide-releasing factor 2 (RASGRF2) -allowed the prediction of metastasis-free cancer and overall survival. In particular, the authors further suggest a common signature of alteration in DNA methylation between gliomas, colon and breast cancers.
Analysing 272 glioblastoma samples with the GoldenGate and Infinium 27K technology, a subgroup of cancers (8.8%) was identified, showing high levels of CpG island methylation 69 . Furthermore, the authors detected a high correlation between hypermethylation and mutation of isocitrate dehydrogenase 1 (IDH1). Mutant IDH1 protein converts α-ketoglutarate into the oncometabolite (R)-2-hydroxyglutarate (2-HG), which is a potent inhibitor of the TET methylcytosine dioxygenase (TET2), which is in turn involved in active DNA demethylation. Using an independent technique and only eight hypermethylated biomarker genes, they confirmed the glioblastoma subtype in an additional cohort of 208 samples, detecting 7.8% to be highly methylated. The novel subtype was even more detectable in low-grade gliomas, with the highest abundance in oligodendrogliomas (93%). Strikingly, DNA methylation status of eight biomarker genes could predict patient survival and hence might be a useful clinical tool for estimating disease prognosis. The results could be confirmed using the higher-resolution Infinium 450K technology analysing more than 450,000 CpG sites 70 
. Seventy-two low-grade gliomas displayed a high correlation between CpG island hypermethylation and patient survival. In addition, the association between high levels of CpG island DNA methylation and IDH1 mutation was empirically and experimentally confirmed 70 . These examples give an outlook on the potential of DNA methylation profiling as an important tool for fine-tuning diagnosis and prognosis. In combination with currently used cytogenetic and genetic markers, DNA methylation might highly improve the prognostic accuracy in the future. Here, classification of newly profiled patient samples by comparing with publicly available reference data sets as discussed above is a possible future scenario (FIG. 2) . Owing to rapidly decreasing sequencing costs, a large number of cancer methylomes will be available soon, which in addition to array-based discovery should allow for the identification of novel prognostic markers in an unbiased manner even outside currently suspected regions of importance.
DNA methylation profiling for disease response Sensitivity to chemotherapeutic drugs is variable between patients and tumour types. However, epigenetic profiling has identified tumour-specific drug-response markers that are capable of predicting response to chemotherapeutic treatment. DNA methylation predictors of the response to chemotherapeutic drugs. The best example of a methylation marker indicating a response to a chemotherapeutic agent is hypermethylation at MGMT in glioma. Its promoter hypermethylation and associated transcriptional repression lead to greater sensitivity to carmustine-and temozolomide-based therapies 5, 71, 72 (FIG. 1) . MGMT protects cells against transition mutations by removing alkyl groups from guanine bases, which are introduced by carcinogens such as nitrosamides. As guanine bases are also alkylated by chemotherapeutic drugs such as carmustine and temozolomide, MGMT expression in tumour cells leads to resistance to these drugs. In cancers that harbour hypermethylated MGMT, the repair mechanism is disabled, leading to sensitivity to alkylating agents 5, 71 .
Hypermethylation of MGMT was first identified in 40% of gliomas and colorectal cancer samples in a study of 500 primary human tumours 72 . Furthermore, NSCLC, lymphomas and head and neck carcinomas revealed hypermethylation of MGMT 72 . A subsequent study of 47 patients with glioma detected 40% of hypermethylated promoters and determined MGMT promoter methylation as a predictor of responsiveness to the alkylating agent carmustine 5 . In this study, MGMT hypermethylation was found to be associated with regression of the tumour and prolonged overall and disease-free survival following treatment with carmustine. Subsequently, MGMT promoter hypermethylation has been associated with treatment outcome of additional alkylating agents, such as temozolomide 71 , and other chemotherapeutic drugs, including cilengitide 73 and cyclophosphamide 74 , as well as radiation 75 . A further example of a DNA methylation event being indicative of successful chemotherapeutic intervention is that of hypermethylation at breast cancer 1, early onset (BRCA1). Mutations in BRCA1, which is a gene involved in DNA repair, have frequently been observed in patients with inherited breast tumours 76 . Furthermore, hypermethylation and associated transcriptional repression of BRCA1 have also been observed in sporadic breast and ovarian cancers 77 . Cancers that are marked by altered BRCA1 expression can be treated with two distinct treatment strategies: conventional chemotherapy or specific inhibition of DNA repair proteins. Triple-negative breast tumours (a breast cancer subtype that lacks the expression of v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2 (ERBB2; also known as HER2/neu) as well as the oestrogen and progesterone receptors), showing frequent hypermethylation of BRCA1 (REF. 78 ), were associated with an improved response to cytotoxic drugs such as cisplatin 79 . In addition, BRCA1 gene mutation carriers benefit from a targeted therapy using inhibitors of PARP, which area proteins that are involved in base excision repair (that is, a DNA repair mechanism that is distinct from homologous recombination, in which BRCA1 is involved) 80 . Two Phase II trials are currently ongoing that aim to establish the efficiency of PARP inhibitors in the treatment of BRCA1-mutated breast and ovarian cancers. Consequently, it is tempting to speculate that PARP inhibitors might also successfully target sporadic cases that are positive for promoter BRCA1 methylation 81 .
Perspectives in personalized medicine
We now have ever-growing numbers of reported epigenetic alterations in disease, and this offers a chance to increase sensitivity and specificity of future diagnostics and therapies.
In order for this to be realized, further reference disease genomes and DNA methylomes are required, and this is currently on the way to being met. Consortia such as the 1000 Genomes Project for genome sequencing and the Blueprint, IHEC and Roadmap projects for methylome mapping 13, 14 currently aim to generate reference data sets for research and clinical use. Dealing with the huge amount of data produced is the most obvious immediate challenge. Modern cancer management strategies will be required to combine and integrate data from various 'omics' approaches (such as genomics, transcriptomics and epigenomics) to determine profiles predicting disease outcome in terms of patient prognosis and treatment response. The integration of data from different studies and the comparison of epigenetic profiles from normal and diseased tissue will allow the production of predictive models for disease outcomes using epigenetic biomarkers and signatures. As we advance from studying alterations at single loci to entire genomes, groups of disease-specific biomarkers will soon be able to diagnose and to predict disease prognosis more accurately than is possible at present.
For certain diseases, such as prostate 33 and lung cancers 60 , combinations of DNA hypermethylated biomarkers have achieved high sensitivities in the detection of cancer cells and in the prediction of tumour progression, respectively. However, before being of clinical value, in particular detection sensitivity and specificity of biomarkers in biological fluids have to be improved. Here, the combination of different epigenetic, genetic and molecular biomarkers (for example, PSA) could increase diagnostic reliability. Using high-throughput epigenetic-screening approaches, the identification of combinations of biomarkers is now achievable for other less well-characterized cancer types. In addition, the increased resolution of DNA methylation profiling might further increase the number of reliable biomarkers for well-studied diseases. However, owing to high costs of high-resolution techniques, these approaches are currently only applicable to marker identification, but for clinical assays, single-gene approaches will still be the methods of choice.
The key to successful therapy lies in combinatorial approaches. If we can integrate candidate-altered epigenetic profile gene lists into potent predictive models and combine conventional treatments with novel drugs, we will achieve the low-dose, customized and high-impact treatment we seek.
